Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KaloBios Pharmaceuticals has initiated a blinded, placebo-controlled Phase I/II clinical study of KB002, the company's anti-GM-CSF monoclonal antibody, as a potential treatment for persistent asthma.
Subscribe to our email newsletter
The study, which is being conducted at over five sites in Australia, will enroll up to 24 patients who will receive either KB002 or placebo. Endpoints for the study will include safety, measurements of Forced Expiratory Volume (FEV1, a measurement of expiratory air flow), and inflammatory markers.
Geoffrey Yarranton, KaloBios’s chief scientific officer, said: “Anti-GM-CSF antibody treatment has shown efficacy in animal studies of models of lung inflammation, and we are interested to see if similar pharmacodynamic activity can be reproduced in this patient population.”